1-22913757-A-T
Variant names:
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PVS1_ModerateBS1_SupportingBS2
The NM_001309193.2(EPHB2):c.3055A>T(p.Lys1019*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00216 in 1,606,538 control chromosomes in the GnomAD database, including 72 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as risk factor (no stars).
Frequency
Genomes: 𝑓 0.011 ( 35 hom., cov: 32)
Exomes 𝑓: 0.0012 ( 37 hom. )
Consequence
EPHB2
NM_001309193.2 stop_gained
NM_001309193.2 stop_gained
Scores
1
6
Clinical Significance
Conservation
PhyloP100: 0.261
Genes affected
EPHB2 (HGNC:3393): (EPH receptor B2) This gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. These receptors are composed of an N-terminal glycosylated ligand-binding domain, a transmembrane region and an intracellular kinase domain. They bind ligands called ephrins and are involved in diverse cellular processes including motility, division, and differentiation. A distinguishing characteristic of Eph-ephrin signaling is that both receptors and ligands are competent to transduce a signaling cascade, resulting in bidirectional signaling. This protein belongs to a subgroup of the Eph receptors called EphB. Proteins of this subgroup are distinguished from other members of the family by sequence homology and preferential binding affinity for membrane-bound ephrin-B ligands. Allelic variants are associated with prostate and brain cancer susceptibility. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -3 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0357 CDS is truncated, and there are 0 pathogenic variants in the truncated region.
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.0111 (1684/152300) while in subpopulation AFR AF= 0.0379 (1574/41560). AF 95% confidence interval is 0.0363. There are 35 homozygotes in gnomad4. There are 796 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting
BS2
High Homozygotes in GnomAd4 at 35 AR gene
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EPHB2 | ENST00000400191.7 | c.3055A>T | p.Lys1019* | stop_gained | Exon 17 of 17 | 1 | ENSP00000383053.3 | |||
EPHB2 | ENST00000374630.8 | c.*187A>T | 3_prime_UTR_variant | Exon 16 of 16 | 1 | NM_017449.5 | ENSP00000363761.3 | |||
EPHB2 | ENST00000374632.7 | c.*187A>T | 3_prime_UTR_variant | Exon 16 of 16 | 1 | ENSP00000363763.3 | ||||
EPHB2 | ENST00000374627.1 | c.*1154A>T | downstream_gene_variant | 5 | ENSP00000363758.1 |
Frequencies
GnomAD3 genomes AF: 0.0110 AC: 1675AN: 152182Hom.: 34 Cov.: 32
GnomAD3 genomes
AF:
AC:
1675
AN:
152182
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00288 AC: 679AN: 235858Hom.: 15 AF XY: 0.00206 AC XY: 262AN XY: 127432
GnomAD3 exomes
AF:
AC:
679
AN:
235858
Hom.:
AF XY:
AC XY:
262
AN XY:
127432
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00123 AC: 1794AN: 1454238Hom.: 37 Cov.: 31 AF XY: 0.00106 AC XY: 767AN XY: 722618
GnomAD4 exome
AF:
AC:
1794
AN:
1454238
Hom.:
Cov.:
31
AF XY:
AC XY:
767
AN XY:
722618
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0111 AC: 1684AN: 152300Hom.: 35 Cov.: 32 AF XY: 0.0107 AC XY: 796AN XY: 74472
GnomAD4 genome
AF:
AC:
1684
AN:
152300
Hom.:
Cov.:
32
AF XY:
AC XY:
796
AN XY:
74472
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
125
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
406
Asia WGS
AF:
AC:
15
AN:
3478
ClinVar
Significance: risk factor
Submissions summary: Other:1
Revision: no assertion criteria provided
LINK: link
Submissions by phenotype
Prostate cancer/brain cancer susceptibility Other:1
Jun 01, 2006
OMIM
Significance: risk factor
Review Status: no assertion criteria provided
Collection Method: literature only
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at